The Institute for Clinical and Economic Review (ICER) on Thursday, Jan. 9, released its final report on JAK inhibitors for the treatment of rheumatoid arthritis.
ICER reviewed AbbVie’s Rinvoq, Pfizer’s Xeljanx and Eli Lilly’s Olumiant as compared to either a placebo or AbbVie’s Humira.
“Rheumatoid arthritis is a progressively disabling condition, and patients are fortunate to have multiple therapy options — including biosimilars — that effectively slow disease progression,” ICER CSO Pamela Bradt said in a statement. “Many economists might expect medicines to become more affordable in an increasingly crowded therapeutic class; however, because the current rebate structure has erected barriers between patients and several emerging RA therapies, traditional market dynamics have been unable to drive down prices. Therefore, while upadacitinib appears to achieve common thresholds for cost-effectiveness when compared to adalimumab, legitimate questions remain about whether or not adalimumab, launched 17 years ago, is fairly priced to begin with.”
To read the final report by ICER, click here.